BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 17296383)

  • 21. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations.
    Rassweiler JJ; Seemann O; Henkel TO; Stock C; Frede T; Alken P
    J Urol; 1996 Sep; 156(3):1108-13. PubMed ID: 8709319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
    Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
    J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection.
    Hermans BP; Sweeney CJ; Foster RS; Einhorn LE; Donohue JP
    J Urol; 2000 Jun; 163(6):1721-4. PubMed ID: 10799168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
    Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
    BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germ cell tumor associated primitive neuroectodermal tumors.
    Ganjoo KN; Foster RS; Michael H; Donohue JP; Einhorn LH
    J Urol; 2001 May; 165(5):1514-6. PubMed ID: 11342908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage I nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection.
    Nicolai N; Colecchia M; Biasoni D; Catanzaro M; Stagni S; Torelli T; Necchi A; Piva L; Milani A; Salvioni R
    J Urol; 2011 Oct; 186(4):1298-302. PubMed ID: 21849196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.
    Rassweiler JJ; Scheitlin W; Heidenreich A; Laguna MP; Janetschek G
    Eur Urol; 2008 Nov; 54(5):1004-15. PubMed ID: 18722704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
    Yoon GH; Stein JP; Skinner DG
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
    Carver BS; Bianco FJ; Shayegan B; Vickers A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Urol; 2006 Jul; 176(1):100-3; discussion 103-4. PubMed ID: 16753380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection?
    Jacobsen NE; Beck SD; Jacobson LE; Bihrle R; Einhorn LH; Foster RS
    J Urol; 2010 Sep; 184(3):949-53. PubMed ID: 20643453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repeat retroperitoneal lymph node dissection for metastatic testis cancer.
    Sexton WJ; Wood CG; Kim R; Pisters LL
    J Urol; 2003 Apr; 169(4):1353-6. PubMed ID: 12629359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence.
    Nicolai N; Miceli R; Necchi A; Biasoni D; Catanzaro M; Milani A; Piva L; Pizzocaro G; Stagni S; Torelli T; Salvioni R
    Eur Urol; 2010 Dec; 58(6):912-8. PubMed ID: 20817343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection.
    Chang SS; Smith JA; Girasole C; Baumgartner RG; Roth BJ; Cookson MS
    J Urol; 2002 Jul; 168(1):87-92. PubMed ID: 12050498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.